pertuzumab (perjeta) Report issue

Biologics mAb Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2382.0085

United States

$3703.8500 - $5042.8000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( hyaluronidase (human recombinant) (Hylenex), trastuzumab (herceptin), pertuzumab (perjeta) - other name: pertuzumab, trastuzumab, and hyaluronidase-zzxf )

Alternative names

2c4 antibody | moab 2c4 | monoclonal antibody 2c4 | omnitarg | omnitarg, 2c4 | omnitarg perjeta | perjeta | pertuzumab | rg-1273 | rhumab 2c4 | rhumab-2c4

Organizations (230)

Research & Development (230)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (77)

Approved Indications (1)


 

Breast Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (77)


 

Adenocarcinoma (Phase 1/Phase 2)

Adrenal Gland Neoplasms (Phase 2)

Anemia (Phase 1)

Bile Duct Neoplasms (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Brain Neoplasms (Phase 2)

Breast Diseases (Phase 1/Phase 2)

Breast Neoplasms ()

Breast Neoplasms, Male (Phase 1)

Carcinoid Tumor (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Early Phase 1)

Cholangiocarcinoma (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2/Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Endometrial Neoplasms (Phase 2/Phase 3)

Epidermal Growth Factor (Phase 2)

ErbB Receptors (Phase 2)

Esophageal Neoplasms (Phase 3)

Fallopian Tube Neoplasms (Phase 2)

Gallbladder Neoplasms (Phase 2/Phase 3)

Gastrointestinal Neoplasms (Phase 2)

Genes, erbB-2 (Phase 1)

Glioma (Phase 2)

Hamartoma (Phase 2)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 2)

Hemangiosarcoma (Phase 2)

Hodgkin Disease (Phase 1)

Hypertrophy, Left Ventricular (Phase 2)

Inflammatory Breast Neoplasms (Phase 3)

Kidney Neoplasms (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2/Phase 3)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Melanoma (Phase 2)

Meninges (Phase 1/Phase 2)

Multiple Endocrine Neoplasia (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoadjuvant Therapy (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms ()

Neoplastic Cells, Circulating (Phase 2)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2/Phase 3)

Pharmacokinetics (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Primary Myelofibrosis (Phase 1)

Progression-Free Survival (Phase 2)

Prostatic Neoplasms (Phase 2/Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Rocky Mountain Spotted Fever (Phase 3)

Salivary Gland Neoplasms (Phase 2/Phase 3)

Sarcoma (Phase 2)

Skin Neoplasms (Phase 2/Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 3)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2/Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 251
  • # of Trial Organizations: 230

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue